VRC01-CLASS PRECURSOR FREQUENCY IN AN AFRICAN POPULATION IS INFLUENCED BY IGHV1-2 ALLELIC COMPOSITION AND NOT MALARIA EXPOSURE.

Saved in:
Bibliographic Details
Title: VRC01-CLASS PRECURSOR FREQUENCY IN AN AFRICAN POPULATION IS INFLUENCED BY IGHV1-2 ALLELIC COMPOSITION AND NOT MALARIA EXPOSURE.
Authors: Muthui MK; Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya., Kibet C; International AIDS Vaccine Initiative (IAVI), Nairobi, Kenya., Muriuki C; KAVI -Institute of Clinical Research, University of Nairobi, Nairobi, Kenya., Sein Y; Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya., Owuor S; Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya., Kinoti R; Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya., Ogonda W; Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya., Muteti M; Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya., Kalyuzhniy O; IAVI Neutralizing Antibody Centre, The Scripps Research Institute, La Jolla, California, USA.; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.; Centre for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, California, USA., Kimotho J; Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya., Kimani M; Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya., Kamau B; Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya., Owuor DC; Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya., Sincomb T; IAVI Neutralizing Antibody Centre, The Scripps Research Institute, La Jolla, California, USA.; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.; Centre for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, California, USA., Ramko K; Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya., Magura J; Africa Health Research Institute (AHRI), Durban, South Africa., Muia A; KEMRI Centre for Clinical Research (KEMRI-CCR), Nairobi, Kenya., Namwoso L; KEMRI Centre for Clinical Research (KEMRI-CCR), Nairobi, Kenya., Orimbo J; Ahero Clinical Trials Unit, CREATES/KEMRI-CCR, Kisumu, Kenya., Cottrell CA; IAVI Neutralizing Antibody Centre, The Scripps Research Institute, La Jolla, California, USA.; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.; Centre for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, California, USA., Anzala O; KAVI -Institute of Clinical Research, University of Nairobi, Nairobi, Kenya., Ogutu B; KEMRI Centre for Clinical Research (KEMRI-CCR), Nairobi, Kenya.; Ahero Clinical Trials Unit, CREATES/KEMRI-CCR, Kisumu, Kenya., Landais E; IAVI Neutralizing Antibody Centre, The Scripps Research Institute, La Jolla, California, USA.; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.; Centre for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, California, USA., Murungi L; International AIDS Vaccine Initiative (IAVI), Nairobi, Kenya., Sok D; IAVI Neutralizing Antibody Centre, The Scripps Research Institute, La Jolla, California, USA.; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.; Centre for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, California, USA., Schief WR; IAVI Neutralizing Antibody Centre, The Scripps Research Institute, La Jolla, California, USA.; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.; Centre for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, California, USA.; Moderna, Cambridge, MA, USA., Ndungu T; Africa Health Research Institute (AHRI), Durban, South Africa.; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.; Ragon Institute of Mass General Brigham, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.; Institute of Infection, Immunity and Transplantation, University College London, London, UK., Muema D; KAVI -Institute of Clinical Research, University of Nairobi, Nairobi, Kenya.; Africa Health Research Institute (AHRI), Durban, South Africa., Nduati EW; Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya.; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK USA.
Source: Research square [Res Sq] 2026 Jun 24. Date of Electronic Publication: 2026 Jun 24.
Publication Type: Journal Article; Preprint
Journal Info: Country of Publication: United States NLM ID: 101768035 Publication Model: Electronic Cited Medium: Internet ISSN: 2693-5015 (Electronic) Linking ISSN: 26935015 NLM ISO Abbreviation: Res Sq Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2693-5015
DOI:10.21203/rs.3.rs-9732671/v1